BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 14715636)

  • 1. Light-chain only multiple myeloma is due to the absence of functional (productive) rearrangement of the IgH gene at the DNA level.
    Magrangeas F; Cormier ML; Descamps G; Gouy N; Lodé L; Mellerin MP; Harousseau JL; Bataille R; Minvielle S; Avet-Loiseau H
    Blood; 2004 May; 103(10):3869-75. PubMed ID: 14715636
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Promiscuous translocations into immunoglobulin heavy chain switch regions in multiple myeloma.
    Bergsagel PL; Chesi M; Nardini E; Brents LA; Kirby SL; Kuehl WM
    Proc Natl Acad Sci U S A; 1996 Nov; 93(24):13931-6. PubMed ID: 8943038
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High incidence of cryptic translocations involving the Ig heavy chain gene in multiple myeloma, as shown by fluorescence in situ hybridization.
    Avet-Loiseau H; Brigaudeau C; Morineau N; Talmant P; Laï JL; Daviet A; Li JY; Praloran V; Rapp MJ; Harousseau JL; Facon T; Bataille R
    Genes Chromosomes Cancer; 1999 Jan; 24(1):9-15. PubMed ID: 9892103
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular features responsible for the absence of immunoglobulin heavy chain protein synthesis in an IgH(-) subgroup of multiple myeloma.
    Szczepański T; van 't Veer MB; Wolvers-Tettero IL; Langerak AW; van Dongen JJ
    Blood; 2000 Aug; 96(3):1087-93. PubMed ID: 10910926
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genomic characterization of the chromosomal breakpoints of t(4;14) of multiple myeloma suggests more than one possible aetiological mechanism.
    Fenton JA; Pratt G; Rawstron AC; Sibley K; Rothwell D; Yates Z; Dring A; Richards SJ; Ashcroft AJ; Davies FE; Owen RG; Child JA; Morgan GJ
    Oncogene; 2003 Feb; 22(7):1103-13. PubMed ID: 12592397
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fluorescence in situ hybridization analysis shows the frequent occurrence of 14q32.3 rearrangements with involvement of immunoglobulin switch regions in myeloma cell lines.
    Kuipers J; Vaandrager JW; Weghuis DO; Pearson PL; Scheres J; Lokhorst HM; Clevers H; Bast BJ
    Cancer Genet Cytogenet; 1999 Mar; 109(2):99-107. PubMed ID: 10087940
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Insertion of excised IgH switch sequences causes overexpression of cyclin D1 in a myeloma tumor cell.
    Gabrea A; Bergsagel PL; Chesi M; Shou Y; Kuehl WM
    Mol Cell; 1999 Jan; 3(1):119-23. PubMed ID: 10024885
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Illegitimate switch recombinations are present in approximately half of primary myeloma tumors, but do not relate to known prognostic indicators or survival.
    Ho PJ; Brown RD; Pelka GJ; Basten A; Gibson J; Joshua DE
    Blood; 2001 Jan; 97(2):490-5. PubMed ID: 11154227
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dysregulation of cyclin D1 by translocation into an IgH gamma switch region in two multiple myeloma cell lines.
    Chesi M; Bergsagel PL; Brents LA; Smith CM; Gerhard DS; Kuehl WM
    Blood; 1996 Jul; 88(2):674-81. PubMed ID: 8695815
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Light-chain plasma cell myeloma caused by 14q32/IGH translocation and loss of the other allele.
    Nishio Y; Sakai H; Saiki Y; Uchida A; Uemura Y; Matsunawa M; Isobe Y; Kato M; Tomita N; Miura I
    Int J Hematol; 2019 May; 109(5):572-577. PubMed ID: 30887274
    [TBL] [Abstract][Full Text] [Related]  

  • 11. IgH translocations in multiple myeloma: a nearly universal event that rarely involves c-myc.
    Bergsagel PL; Nardini E; Brents L; Chesi M; Kuehl WM
    Curr Top Microbiol Immunol; 1997; 224():283-7. PubMed ID: 9308253
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Long distance vectorette PCR for detecting translocation of IgH gene in switch regions of patients with multiple myeloma].
    Guo C; Huo J; Jiang H
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2005 Jun; 13(3):460-3. PubMed ID: 15972142
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel chromosomal translocation t(4; 14)(p16.3; q32) in multiple myeloma involves the fibroblast growth-factor receptor 3 gene.
    Richelda R; Ronchetti D; Baldini L; Cro L; Viggiano L; Marzella R; Rocchi M; Otsuki T; Lombardi L; Maiolo AT; Neri A
    Blood; 1997 Nov; 90(10):4062-70. PubMed ID: 9354676
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Complex biallelic IGH rearrangements in IgM-expressing Z-138 cell line: Involvement of downstream immunoglobulin class switch recombination.
    Guikema JE; Fenton JA; de Boer C; Kleiverda K; Brink AA; Raap AK; Estrov Z; Schuuring E; Kluin PM
    Genes Chromosomes Cancer; 2005 Feb; 42(2):164-9. PubMed ID: 15543623
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rapid amplification of immunoglobulin heavy chain switch (IGHS) translocation breakpoints using long-distance inverse PCR.
    Sonoki T; Willis TG; Oscier DG; Karran EL; Siebert R; Dyer MJ
    Leukemia; 2004 Dec; 18(12):2026-31. PubMed ID: 15496980
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Translocation of an antibody transgene requires AID and occurs by interchromosomal switching to all switch regions except the mu switch region.
    Shansab M; Eccleston JM; Selsing E
    Eur J Immunol; 2011 May; 41(5):1456-64. PubMed ID: 21469111
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genetics and cytogenetics of Waldenstrom's macroglobulinemia.
    Schop RF; Fonseca R
    Semin Oncol; 2003 Apr; 30(2):142-5. PubMed ID: 12720124
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of MYC translocations in multiple myeloma cell lines.
    Dib A; Gabrea A; Glebov OK; Bergsagel PL; Kuehl WM
    J Natl Cancer Inst Monogr; 2008; (39):25-31. PubMed ID: 18647998
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recurrent immunoglobulin gene translocations identify distinct molecular subtypes of myeloma.
    Chesi M; Kuehl WM; Bergsagel PL
    Ann Oncol; 2000; 11 Suppl 1():131-5. PubMed ID: 10707795
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High incidence of translocations t(11;14)(q13;q32) and t(4;14)(p16;q32) in patients with plasma cell malignancies.
    Avet-Loiseau H; Li JY; Facon T; Brigaudeau C; Morineau N; Maloisel F; Rapp MJ; Talmant P; Trimoreau F; Jaccard A; Harousseau JL; Bataille R
    Cancer Res; 1998 Dec; 58(24):5640-5. PubMed ID: 9865713
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.